β-1,3/1,6-D-glucan
ApprovedSmall molecule
β-1,3/1,6-D-glucan is one of 9 small molecule programs targeting Aggressive Periodontitis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Aggressive Periodontitis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 3
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 3
Triclosan
CColgate Palmolive
Approved
Amoxicillin and Metronidazole
UUniversity of Campinas, Brazil
Approved
β-1,3/1,6-D-glucan
AAl-Azhar University
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
Biaxin
AbbViePreclinical
Systemic Antibiotics
BBioTissue Holdings, Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Aggressive Periodontitis1 trial
Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis
Completed·—·Phase 4·NCT02402296·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for β-1,3/1,6-D-glucan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAl-Azhar University